Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older.
Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open in Canada, Australia, the UK and several countries in Europe for eligible patients with Alagille syndrome.
Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for maralixibat for the treatment of cholestatic liver disease in patients with Alagille syndrome.
Mirum’s second investigational treatment, volixibat, also an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the OHANA Phase 2b study for pregnant women with intrahepatic cholestasis of pregnancy, VISTAS Phase 2b study for adults with primary sclerosing cholangitis, and the VANTAGE Phase 2b study for primary biliary cholangitis.
Location: United States, California, Foster City
Employees: 51-200
Phone: +1 650-667-4085
Total raised: $120M
Founded date: 2018
Investors 3
Date | Name | Website |
06.07.2021 | New Enterp... | nea.com |
- | Frazier Li... | frazierls.... |
25.10.2023 | Longitude ... | longitudec... |
Funding Rounds 1
Date | Series | Amount | Investors | Deal News |
07.11.2018 | Series A | $120M | New Enterp... | vcnewsdail... |
Mentions in press and media 12
Date | Title | Description | Source |
13.04.2021 | Vivet Therapeutics, participada por Ysios Capital y Columbus... | 13/04/2021 Nota de prensa MIRUM PHARMACEUTICALS Y VIVET THERAPEUTICS FIRMAN UN ACUERDO EXCLUSIVO D... | webcapital... |
13.04.2021 | Vivet Therapeutics, participated by Ysios Capital and Columb... | 13/04/2021 Press release MIRUM PHARMACEUTICALS AND VIVET THERAPEUTICS ENTER INTO EXCLUSIVE WORLDWI... | webcapital... |
10.03.2021 | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq... | FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar 10, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) tod... | oaoa.com/n... |
30.12.2020 | Mirum Pharmaceuticals, Inc. announced that it has received $... | On December 30, 2020, Mirum Pharmaceuticals, Inc. (NasdaqGM:MIRM) closed the transaction. The compan... | marketscre... |
07.11.2018 | Deerfield Management Joins $120M Series A for Mirum Pharmace... | Mirum Pharmaceuticals today announced that it has secured $120 million in Series A financing to supp... | citybizlis... |
07.11.2018 | Term Sheet — Wednesday, November 7 | 5 Qs WITH A DEALMAKER Good morning, Term Sheet readers. Paid Content You can't secure what you can... | fortune.co... |
07.11.2018 | Mirum Pharmaceuticals Secures $120M in Series A Financing | Mirum Pharmaceuticals, a San Diego, CA-based clinical-stage therapeutics company, secured $120m in S... | finsmes.co... |
07.11.2018 | NEA Leads $120M Series A for Mirum Pharmaceuticals | Mirum Pharmaceuticals today announced that it has secured $120 million in Series A financing to supp... | citybizlis... |
07.11.2018 | Mirum Pharmaceuticals Inks $120M in Series A | SAN DIEGO, CA, Mirum Pharmaceuticals today announced that it has secured $120 million in Series A ... | vcnewsdail... |
- | Mirum Pharmaceuticals and Vivet Therapeutics Enter into Excl... | – Mirum expands potential opportunities across rare disease pipeline – Vivet to lead preclinical de... | healthcap.... |
Show more